NeuroSense Therapeutics Ltd. (NRSN)

$1.84

0.00 (0.00%)
Rating:
Recommendation:
-
Symbol NRSN
Price $1.84
Beta 0.000
Volume Avg. 0.14M
Market Cap 21.480M
Shares () -
52 Week Range 1.23-8.18
1y Target Est -
DCF Unlevered NRSN DCF ->
DCF Levered NRSN LDCF ->
ROE -
ROA -
Operating Margin -
Debt / Equity 13.34% Neutral
P/E -
P/B -
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest NRSN news


Healthcare
Biotechnology
NASDAQ Capital Market

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. Its lead product is PrimeC, an extended-release oral formulation of a fixed dose combination of ciprofloxacin and celecoxib for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.